Compare ATRO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRO | AUPH |
|---|---|---|
| Founded | 1968 | 1993 |
| Country | United States | Canada |
| Employees | 2700 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1995 | 2014 |
| Metric | ATRO | AUPH |
|---|---|---|
| Price | $59.45 | $16.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $98.00 | $18.00 |
| AVG Volume (30 Days) | 457.5K | ★ 739.2K |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 276.09 | N/A |
| EPS | ★ 1.31 | 0.76 |
| Revenue | ★ $862,128,000.00 | $283,055,000.00 |
| Revenue This Year | $19.84 | $16.68 |
| Revenue Next Year | $9.74 | $17.60 |
| P/E Ratio | $47.76 | ★ $32.44 |
| Revenue Growth | ★ 8.39 | N/A |
| 52 Week Low | $41.50 | $12.79 |
| 52 Week High | $99.89 | $19.25 |
| Indicator | ATRO | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 50.56 |
| Support Level | $56.20 | $15.27 |
| Resistance Level | $78.00 | $17.16 |
| Average True Range (ATR) | 2.76 | 0.45 |
| MACD | 0.24 | 0.03 |
| Stochastic Oscillator | 34.35 | 41.54 |
Astronics Corporation is a provider of technologies to the aerospace, defense, and electronics industries, offering high-performance electrical power generation and distribution systems, motion systems, lighting and safety systems, avionics products, systems certification, aircraft structures, and automated test systems. The company operates through two reportable segments, Aerospace and Test Systems. The Aerospace segment designs and manufactures products for the aerospace and defense industry and generates the majority of revenue, while the Test Systems segment designs, develops, manufactures, and maintains automated test systems for the aerospace and defense, communications, and mass transit industries. The company derives the majority of its revenue from the United States.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.